Table 1.
Patient demographics and baseline characteristics (pooled data from Study 1 and Study 2)
| N = 18 | |
|---|---|
| Median age (range), y | 63 (25–75) |
| Gender, n (%) | |
| Male | 10 (56) |
| Female | 8 (44) |
| ECOG PS, n (%) | |
| 0 | 7 (39) |
| 1 | 10 (56) |
| 2 | 1 (6) |
| Tumor type, n (%) | |
| Colorectal cancer | 6 (33) |
| Renal cell cancer | 2 (11) |
| Liposarcoma | 2 (11) |
| Other a | 8 (44) |
| No. of prior systemic treatment regimens, n (%) | |
| 1 | 3 (17) |
| 2 | 1 (6) |
| 3 | 5 (28) |
| 4 | 4 (22) |
| ≥5 | 5 (28) |
| Concurrent antihypertensive agent, n (%) | |
| Yes | 6 (33) |
| No | 12 (67) |
aOvarian cancer; non-small cell lung cancer; thymic cancer; synovial sarcoma; esophageal malignant melanoma; hypopharynx cancer; gastric cancer; pancreatic cancer
ECOG PS Eastern Cooperative Oncology Group performance status